Project Grant HT94252410340
Award Date
4/15/24
Completion Date
4/14/25
Dollars Obligated
$188K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19111, USA
Similar Awards
The Institute For Cancer Research was awarded a $1,402,500 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 2021 through June 2025 to overcome resistance to EGFR inhibitors in advanced head and neck cancers. The Military Medical Research and Development program supports biomedical research to transform military and public health care through innovative solutions. This...
The Institute For Cancer Research, a non-profit research organization and subsidiary of Temple University, was awarded a $534,445 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research to investigate NETRIN G1 ligand as a new immunomodulatory target and early biomarker in pancreatic cancer, with a project period from August 1, 2023 to July 31, 2026. The Institute For Cancer Research has extensive...
The Institute For Cancer Research at Temple University received a $187,000 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The two-year award, which runs from April 1, 2021 through March 31, 2023, will support research into therapeutic targeting of P300/CBP in clear cell renal cell carcinoma. The Military Medical Research and Development program aims to transform military and public...
The Institute For Cancer Research has been awarded a $940,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct a mouse model study of epigenetic events in melanomagenesis. This 3-year grant, with a period of performance from July 1, 2024 to June 30, 2027, will enable the non-profit research organization to investigate the underlying epigenetic mechanisms driving the development of melanoma. As a prime grantee, The...
The Institute For Cancer Research will receive $1,368,836 under a three-year Project Grant from the Department of the Army Medical Command to investigate the role of the acetyl-CoA pathway in resistance to anti-androgen therapy. Funded through the Military Medical Research and Development program (CFDA 12.420), this research aims to transform health care for service members and the public by investigating medical solutions for the battlefield and innovative biomedical research. The awardee,...
The federal Project Grant award of $564,000.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research by The Institute For Cancer Research to explore the role of MUL1 in prostate tumorigenesis. The award, with a performance period from May 1, 2025 to April 30, 2027, will fund sophisticated cancer research focused on developing innovative approaches to prostate cancer prevention, diagnosis, and treatment. The Institute...
The U.S. Defense Health Agency awarded a $1,880,000 Project Grant to The Institute for Cancer Research, a non-profit subsidiary of Temple University, under the Military Medical Research and Development program (CFDA 12.420). The funding will support a 3-year research project to study the SRPK1-AKT signaling axis in endometrial cancer. As a prime grantee, The Institute for Cancer Research will conduct preclinical testing and analysis to develop new approaches for cancer prevention and...
The Department of the Army Medical Command awarded a $475,457 Project Grant to the Institute of Cancer Research: Royal Cancer Hospital in the United Kingdom. The grant is part of the Military Medical Research and Development program (CFDA 12.420) and will fund research characterizing biomarkers of growth and progression in small renal masses from September 30, 2022 to September 29, 2025. Through this award, the grantee will investigate medical solutions for the battlefield by transforming...
This $188,000 Project Grant was awarded on April 1, 2024 by the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), to The Institute For Cancer Research. The grant funds a research project titled "P2X7 RECEPTOR AS A NOVEL THERAPEUTIC TARGET IN PROSTATE CANCER" that will be conducted from April 1, 2024 through March 31, 2026. The Institute For Cancer Research, a non-profit subsidiary of Temple University, will carry out biomedical research...
The federal Project Grant award in the amount of $499,999.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), funds research by the Institute of Cancer Research: Royal Cancer Hospital (The) to study the interplay of molecular and spatial architectures with clinical states in prostate cancer. The research project aims to make discoveries that defeat cancer through innovative biomedical research. As a subawardee, the Institute of...